We are pioneering a new class of precision therapeutics by targeting the protein interactome - an exponentially larger druggable space than the traditional druggable genome. We are powered by a proprietary platform developed at HMS that can modulate the interactions of multisubunit protein complexes, unlocking many first-in-class targets with the potential for significantly enhanced safety and efficacy.